Special Issue

Radiotherapy for Gastrointestinal Cancer

Message from the Guest Editors

The focus of this Special Issue is on radiotherapy for gastrointestinal cancer. GI cancers account for 26% of the global cancer incidence burden and 35% of all cancer-related deaths, therefore, presenting a major health problem. These tumors frequently require a multimodal treatment including a combination of radiotherapy, surgery, and chemotherapy. Recent advances in modern medical imaging and radiotherapy technologies have improved the effectiveness. decreased the complications, and expanded the implications of radiotherapy. We expect that the study of radiotherapy, combined with immunotherapy, novel radio-sensitizers, or radio-protectors, will improve the efficacy and safety of radiotherapy. In this Special Issue, we invite your contributions, either in the form of original research articles, reviews, or shorter perspective articles on all aspects related to the theme of "radiotherapy for gastrointestinal cancer" including radiation biology, physics, and oncology.

Guest Editors

Prof. Dr. Chi Lin

Department of Radiation Oncology, University of Nebraska Medical Center, 987521 Nebraska Medical Center, Clarkson Tower, Omaha, NE 68198, USA

Prof. Dr. Benhua Xu

Department of Radiation Oncology, Fujian Medical University Union Hospital, Fuzhou, China

Dr. Terence T. Sio

Mayo Clinic Scottsdale-Phoenix, Arizona, Scottsdale, AZ, USA

Deadline for manuscript submissions

closed (15 December 2023)



Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed



mdpi.com/si/124322

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com_

mdpi.com/journal/cancers





Cancers

an Open Access Journal by MDPI

Impact Factor 4.4 CiteScore 8.8 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok.

Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)

